| Is 18F FDG PET-CT cost effective in lung cancer? | |
| | |
MedLine Citation:
|
PMID: 17428168 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Medical advances are often technology driven. One of the new technologies used in imaging is the positron emission tomography (PET)-computed tomography (CT) scanner, which combines the advantages of the functional imaging of PET with CT. This enables both functional and anatomical data to be acquired at the same time. However, such technology is expensive and not always widely available. In the assessment of patients suffering from non-small-cell lung cancer the only curative treatment is surgery or radical radiotherapy, but this is only possible if disease is limited to the affected lung and local nodes. Imaging with CT has not been reliable in determining disease load and many patients undergo futile thoracotomies, which are both expensive and also carry a significant morbidity. In this clinical scenario there is evidence that (18)F fluorodeoxyglucose PET-CT is the best discriminator of disease load and, if used in the correct clinical setting, will not only reduce the number of futile operations but also reduce costs. |
| | |
Authors:
|
John Buscombe; E O'Rourke |
Related Documents
:
|
19333688 - Role of carbon-11 choline pet/ct in the management of uterine carcinoma: initial experi... 17893588 - Nasopharyngeal carcinoma: the role of magnetic resonance imaging in diagnosis, staging,... 19626378 - Additional value of fdg-pet/ct in management of "solitary" liver metastases: preliminar... 14499138 - Conventional imaging and 2-deoxy-2-[18f]fluoro-d-glucose positron emission tomography f... 19333688 - Role of carbon-11 choline pet/ct in the management of uterine carcinoma: initial experi... 11293898 - Quality assurance in gynecologic cytology. the value of cytotechnologist-cytopathologis... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert review of anticancer therapy Volume: 7 ISSN: 1744-8328 ISO Abbreviation: Expert Rev Anticancer Ther Publication Date: 2007 Apr |
Date Detail:
|
Created Date: 2007-04-12 Completed Date: 2007-05-31 Revised Date: 2007-12-05 |
Medline Journal Info:
|
Nlm Unique ID: 101123358 Medline TA: Expert Rev Anticancer Ther Country: England |
Other Details:
|
Languages: eng Pagination: 471-6 Citation Subset: IM |
Affiliation:
|
Royal Free Hospital, Nuclear Medicine, London, UK. j.buscombe@medsch.ucl.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cost-Benefit Analysis Fluorodeoxyglucose F18 / diagnostic use, economics* Humans Lung Neoplasms / diagnosis*, economics* Positron-Emission Tomography / economics*, instrumentation Tomography, X-Ray Computed / economics*, instrumentation |
| Chemical | |
Reg. No./Substance:
|
63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Perspectives of clinical proteomics in gastrointestinal cancer.
Next Document: Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future.